Woodcast was awarded in the New tree 2014 competition

Woodcast casting material made from pure wood and biodegradable plastic is a winner in the series Demograhpic changes of New tree 2014 competition.

The jury assessed Woodcast as follows:

“In this concept interesting is the new context of use of wood as a casting material and, above all, the user-oriented development. The identification of needs of various different user groups is a good place to start developing next prototypes of this product.”
“Innovative. Recyclability good.”
“Very creative solution to the basic process of everyday health care. The operational characteristics allow flexible use of the product.”

(more…)

Read More

Herantis Pharma has initiated Phase 2 study with Cis-UCA Eye Drops in Patients with Dry Eye Syndrome, results expected in Q3/2015

Herantis Pharma has initiated Phase 2 study with Cis-UCA Eye Drops in Patients with Dry Eye Syndrome, results expected in Q3/2015

Herantis Pharma Plc.
Company release 7 January 2015 at 9:00 am

Herantis Pharma Plc. has initiated its Phase 2 clinical study with Cis-UCA Eye Drops in patients with Dry Eye Syndrome. In the study, 150 patients with Dry Eye Syndrome will be randomized to receive 4 weeks of treatment with either placebo eye drops or two different strengths of cis-UCA Eye Drops. The objective of the study is to compare the safety and efficacy of Cis-UCA Eye Drops to placebo, for the treatment of the signs and symptoms of Dry Eye Syndrome.

(more…)

Read More

Herantis Pharma announces FDA clearance of IND for Phase 2 study of Cis-UCA Eye Drops

Herantis Pharma announces FDA clearance of IND for Phase 2 study of Cis-UCA Eye Drops

Herantis Pharma plc.
Company release 8 September 2014 at 8:30 a.m.

The United States Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) of Herantis Pharma Plc. for a Phase 2 clinical study of Cis-UCA Eye Drops for the treatment of Dry Eye Syndrome. Patient enrolment in the clinical study is planned to start by the end of 2014.

(more…)

Read More

BioSilta Completes EUR 2.5 Million ($3.4 Million) Funding Round

Investment will be used to support commercial expansion in Europe and the USA

Cambridge, UK, 11th June 2014: BioSilta Ltd, a developer of advanced microbial growth systems, today announced that it has received EUR 2.5 million from Omega Funds (London) and existing investor Inveni Capital (Helsinki). The funding will be used to support commercial expansion through direct sales and marketing teams in Europe and the USA, and the establishment of distribution networks in other regions to increase sales of the Company’s EnPresso® product line. The investment will also be used to accelerate the introduction of new products in BioSilta’s pipeline.

(more…)

Read More

Medeia Therapeutics Ltd to participate in a new EU Project

Medeia Therapeutics announced today that European Commission has granted 3.4 million EUR to fund a new Marie Curie Initial Training Network called “nEUROinflammation”. In addition to Medeia 12 other partner organizations from industry and academia in 9 European countries will be investigating inflammatory processes in the brain with a common aim to improve therapeutic opportunities especially for stroke and multiple sclerosis. (more…)

Read More

Medtentia Helix Ring for Mitral Valve Repair Continues to Achieve All Objectives in Approval Study

Press release
Helsinki, Finland, July 31, 2013
Medtentia Helix Ring for Mitral Valve Repair Continues to Achieve All Objectives in Approval Study

Medtentia International Ltd Oy today announced that the surgeons at Helsinki University Hospital led by Prof Werkkala have successfully continued to recruit patients for the official second phase of the clinical approval study evaluating the safety and efficacy of the “Medtentia Helix Ring in Adults Undergoing Mitral Valve Repair Surgery”. (more…)

Read More

BioSilta introduces EnPresso B growth systems for bacterial cultures

Systems increase yields and improve functionality of recombinant proteins

BioSilta Oy, a developer of advanced microbial growth systems, today announced the commercial launch of the first products in its proprietary EnPresso® B range of reagent-based growth systems for bacterial cultures. Extensive results from independent labs around the world have confirmed that these new products typically increase protein yields by five to 100-fold and improve protein functionality when compared to results using conventional growth media. (more…)

Read More